• Menu
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Before Header

  • About Us
  • Lexicon
  • Contact Us
  • Our Store
  • ↑
  • ↓

Balloon Juice

Come for the politics, stay for the snark.

No one could have predicted…

Sometimes the world just tells you your cat is here.

Let me file that under fuck it.

We will not go back.

Fight for a just cause, love your fellow man, live a good life.

Republicans want to make it harder to vote and easier for them to cheat.

I really should read my own blog.

We will not go quietly into the night; we will not vanish without a fight.

Dear media: perhaps we ought to let Donald Trump speak for himself!

Speaker Mike Johnson is a vile traitor to the House and the Constitution.

You cannot shame the shameless.

This is dead girl, live boy, a goat, two wetsuits and a dildo territory.  oh, and pink furry handcuffs.

Welcome to day five of every-bit-as-bad-as-you-thought-it-would-be.

Republicans seem to think life begins at the candlelight dinner the night before.

If you can’t control your emotions, someone else will.

The rest of the comments were smacking Boebert like she was a piñata.

This really is a full service blog.

We cannot abandon the truth and remain a free nation.

Keep the Immigrants and deport the fascists!

Speaking of republicans, is there a way for a political party to declare intellectual bankruptcy?

Roe is not about choice. It is about freedom.

When we show up, we win.

“I was told there would be no fact checking.”

Perhaps you mistook them for somebody who gives a damn.

Mobile Menu

  • 2026 Targeted Political Fundraising
  • Donate with Venmo, Zelle & PayPal
  • Site Feedback
  • War in Ukraine
  • Submit Photos to On the Road
  • Politics
  • On The Road
  • Open Threads
  • Topics
  • Authors
  • About Us
  • Contact Us
  • Lexicon
  • Our Store
  • Politics
  • Open Threads
  • 2026 Activism
  • Garden Chats
  • On The Road
  • Targeted Fundraising!
You are here: Home / Archives for Tom Levenson

Tom has been a Balloon Juice writer since 2010.

Tom Levenson

My AI Told Me So!

by Tom Levenson|  April 14, 20261:38 pm| 122 Comments

This post is in: Healthcare, Open Threads, Science & Technology

Crossposted at Inverse Square. (Most of what I post there comes here as well, though not quite all. There’s no paywall, so if y’all would like to be notified when something goes up, that’s where you can do so.)

———————

I teased this story in a post last week: in 2024 a team of researchers from the University of Gothenberg in Sweden put up two papers on a preprint server, describing yet another new malady induced by our our screen-dominated age: bixonimania.

In that literature bixonimania was presented as a minor condition, something to be aware of more than worried about. In the papers it was described as the result of overexposure to blue light—as in that which shines off the screens so many of us are glued to these days. It manifested itself when a victim rubbed their eyes too much, leading to the not-very-terrfiying symptom in which the patient’s eyelids turned a faint pink.

So—one more morsel tossing in the sea of major and minor results cast into the scientific publication ocean. A discovery that would be of no great import to anyone beyond, perhaps, a tiny cohort of specialists.

Except for one thing…

It was all a lie.

The papers were invented; the lead author was a fake, complete with an AI generated photo, and the Swedish scientists who created the fictional reports weren’t ophthalmologists but researchers interested in the brave new world that AI—specifically large language models (LLMs)—are creating for us.

What they found is first funny and then chilling. The whole story is well told by Chris Stokel-Walker, writing in Nature. Within weeks of posting the two fakes, major LLMs started to refer to bixonimania as real. Bing, Gemini, Perplexity, ChatGPT—they all fell for it. As Stokel-Walker documents, in time, the “disease” migrated into the published scientific literature, leading to the embarrassment of a retraction.

The funny part is that the Swedish team, led by Almira Osmanovic Thurnström, larded their hoax with brutally clear signals that something was awry. Among the ones Stokel-Walker listed, my favorite came in one the acknowledgements sections: a shout out to “Professor Maria Bohm at The Starfleet Academy for her kindness and generosity in contributing with her knowledge and her lab onboard the USS Enterprise.” That should give one pause, shouldn’t it? And if that weren’t enough, the researchers included lines like “this entire paper is made up.”

Nuff said.

Except, and this is the proximate point of this post, this is a reminder that LLMs are not in fact thinking machines. They are simulations of reasoning beings, built not on comprehension but statistical inference. And as such, they are, clearly game-able.

LLM Follies--Dread Catarrh Edition

So that’s one worry: what we know will become what we might know, as mis- or disinformation pollutes the data which feeds our seemingly hyper-competent AI assistants. The possibilities for actively malign outcomes are obvious. Explicitly bad actors could game the LLM ecosystem by injecting supporting “data” for their particular grifts by spamming the online literature with seemingly plausible scientific results. If we’re talking medicine and health, the harms that could flow from such scams are frightening.

But beyond that concern, real and major as it is, there was a more general issue raised for me by bixonimania’s arrival on the scene: how it will play into the war on expertise built in to the “do your own research” strain of “alt-health” folly.

That notion: that experts conceal facts for corrupt reasons and a dedicted amateur researcher can penetrate behind that wall of lies to the “real” story of vaccines—which is what I’m currently most obsessed with—lies at the heart of the powerful and effective messages delivered by anti-vax influencers, led by their grifter in chief, Robert Kennedy Jr., and those around him.

The flaw in the notion that simple sitzfleisch and the ability to run searches on the internet will reliably reveal the truth about vaccination is that damned hard to assess information about particular vaccines and the scientific disciplines that underly the study of vaccination without a meaningful grasp of immunology, modern molecular biology, microbiology and more. Especially when one already knows the answer (RFK Jr. never met a vaccine he didn’t loathe) It’s way too easy to find correlations (or seeming associations that turn out not to exist at all), then leap to claims of causation that don’t hold up.

That’s happened a lot before AI came on the scene, of course. But given this demonstration of current LLMs’ deeply flawed bullshit detectors (Starfleet Academy? I mean, really…) it seems likely that this technology will only make it enhance the vaccine denialists’ ability to reinforce their believers’ confidence in things that ain’t so. Imagine how many “studies” that prove vaccines are bad could be generated to “teach” our LLM friends—who could then deliver that good (bad) news to those on the hunt for reasons to avoid the greatest life-saving technology humankind has ever gifted itself.

I haven’t got any obvious solution—except, perhaps, to hold AI providers responsible for harms born of their products functioning as designed. But the real issue is human: how to persuade our society to accept the division of labor required to live together.

We have to recognize that we can’t all be brain surgeons, or plumbers–or vaccinologists –and that those who are do in fact have distinct expertise that the rest of us can depend on.

And with that…

This thread is as open as current AI is gullible.

Image: Francisco Goya, The Sleep of Reason Produces Monsters, c. 1799

My AI Told Me So!Post + Comments (122)

More Vaccine Follies + A Respite That Might Not Be As Relaxing As One Might Hope

by Tom Levenson|  April 8, 20267:34 pm| 28 Comments

This post is in: Healthcare, Open Threads, Republican Stupidity, Science & Technology

Crossposted at Inverse Square. (Most of what I post there comes here as well, though not quite all. There’s no paywall, so if y’all would like to be notified when something goes up, that’s where you can do so.)

——————

With Armageddon postponed (perhaps—the afternoon news is not terribly reassuring) there’s a bit of space to return to domestic matters.

There’s been a lot of vaccine and public health news coming out over the last couple of weeks, almost all of it understandably obscured by the torrent of war news. Too much of it has been bad—and we’ll get to some of the lowlights over the next few days.

For now, I want to draw your attention to yet another wholly unforced error that is about to threaten the lives and/or wellbeing of American kids for exactly zero good reasons. (And I need to thank our own Adam Silverman, who sent me the first article I read on this.)

There’s a bacterium at the heart of the story, Haemophilus influenzae type b, better now as Hib.

Hib is a nasty customer. When it invades a victim it can produce a bestiary of rotten illnesses—pneumonia, meningitis, cellulitis and several more. It mostly strikes kids, though there are other risk factors. If you’re lucky, all you get is mild ear infection. If not, increasingly severe outcomes come onto the table, including lasting brain damage and death.

More Vaccine Follies + A Respite That Might Not Be As Relaxing As One Might Hope

Up until 1980, as many as 20,000 young children would suffer serious Hib infections. On average, 1,000 died. Then the first Hib vaccine appeared, to be followed by other formulations. Kids can receive the first of the Hib series as young as 6 weeks. When the immunization series is complete, the shots are 93-100% effective in preventing disease. As a result, the US currently sees about 50 cases of Hib a year, and the CDC tells us, “most of these cases are in children who didn’t get any or all of the recommended Hib shots.” As MSN reporter Erika Edwards writes, “many doctors who’ve trained in the past 40 years have never seen a case.”

That may be changing. Vaccination rates for Hib have already started to fall—slightly so far, but with the sustained attack on vaccines mounted by RFK Jr.’s HHS the risk is that Hib vaccine use will decline more and more rapidly.

If so we’re going to see a lot more of this:

Dr. Kathryn Edwards, a vaccine safety expert and professor of pediatrics at Vanderbilt University Medical Center in Nashville, Tennessee, said her colleagues recently treated two cases of Hib-related meningitis. Previously, Vanderbilt hadn’t had such a case for “a number of years,” she said.

Dr. Eehab Kenawy, a pediatrician in Panama City, Florida, said that in December, the local hospital’s intensive care unit treated two young children with Hib who were visiting the area from other states. One was a 2-year-old, he said. The other was a 4-month-old who died. “Both were unvaccinated,” he said.

Hib is an almost wholly vaccine-preventable disease. If a community vaccinates itself at a high enough level, even those kids too young to have completed the full series of shots will be protected, as the bacterium wouldn’t be able to find a crack in that wall of immunization. Neither of those two babies had to die. Neither of them should have died. Their blood is on Kennedy’s hands, and on all those who have made names and money for themselves as anti-vaccine influencers and activists.

What gets me is that this is not a new story (which is, of course, a running theme in my upcoming A Pox on Fools). The pattern that Hib is likely to follow is already well known. If the current anti-vax movement continues to hold power, eventually a major outbreak will occur. A bunch of kids will die and more will be permanently injured. That will scare parents back into their pediatricians’ offices and vaccine rates will tick up. Until a long enough time has passed without significant Hib numbers, and in the resulting amnesia, the cycle can begin again.

We can do better, and I do think we will–but only after we’ve exhausted all other options (thanks, Winnie). But I don’t know how many people will be hurt or buried before we get there.

After all that…how about a respite, or perhaps a tease…

Here’s my favorite story so far this week.

Have you heard of bixonimania? I very much hope not, because this disease, allegedly caused by overexposure to blue light caused by staring too much at your screens, sounds serious, but for one thing…

It doesn’t exist.

The article linked above, published in the journal Nature, tells the whole, hilarious, scary story.

Funny? Yes: the paper announcing the existence of the condition included lines like this one, thanking “Professor Maria Bohm at The Starfleet Academy for her kindness and generosity in contributing with her knowledge and her lab onboard the USS Enterprise.”

Scary? Oh yeah…despite many such clearly legible signposts, as Chris Stokel-Walker writes in the Nature piece, leading AI models scraped up the designed hoax and reported out bixonomania as fact. That has implications that are not good at all, especially in this “do your own research” era of medical degrees gained at the University of Google (or LLMs.)

More to come on this one.

And in the meantime…this thread is as open as a holodeck on Halloween. (How open is that? Hell if I know, but it sounds fun.)

Image: Edvard Munch, Woman with Sick Child. Inheritance, 1905-1906

More Vaccine Follies + A Respite That Might Not Be As Relaxing As One Might HopePost + Comments (28)

It Was Nice While It Lasted…The US Surrenders on Science

by Tom Levenson|  April 5, 20268:31 pm| 40 Comments

This post is in: Open Threads, Republican Stupidity, Science & Technology

Crossposted in very slightly different form at Inverse Square.

On April 2, 2026, the leading US scientific journal, Science, reported a long-expected piece of news:

China’s overall spending on R&D has topped that of the United States—at least by one widely used measure. In 2024, China spent $1.03 trillion on research whereas the U.S. spent $1.01 trillion when adjusted for purchasing power, according to the 31 March edition of science and technology indicators compiled by the Organisation for Economic Co-operation and Development.

I suppose that if one roots for one side or the other, a US fan could take solace in the fact that their team is still well ahead on spending per capita. Cold comfort though, against the hard truth that the US, the dominant research power globally since the end of World War 2, is surrendering its seven decades of scientific primacy. With that shift, the US loses not just the prestige of uncovering fundamental knowledge of nature, but the economic impact of robust scientific infrastructure that generations of Americans have come to expect.

It Was Nice While It Lasted...

This shift has been coming for a while, but it has been actively advanced by Donald Trump’s incomprehensibly stupid policy choices—gutting scientific research performed within the federal government while progressively starving academic inquiry funded by agencies like the NSF and the NIH:

For the second year in a row, US President Donald Trump has proposed significant cuts to the budgets of major US science agencies…

The plan proposes cuts to federal agencies that fund or conduct research on health, space and the environment. Some of the steepest cuts would be made to the National Science Foundation (NSF) and the Environmental Protection Agency(EPA): the budgets of both would fall more than 50% in 2027 compared to their current levels (see ‘Budget crunch’). The budget for the US National Institutes of Health would drop 13%.

Congress may and likely will mitigate this scorched earth attack on the US’s research capacity, but fighting ferocious battles year over year just to remain more or less at prior years’ funding still leads to lasting decline. Anyone with alternatives will be strongly incentivized to head elsewhere, and no one with options would choose to come here for a research career. The brain drain from the rest of the world that has so benefitted the US since the middle of the last century is now reversing. We’ll feel the consequences—among them, economic disadvantage compared to our competitor states—for decades.

Which is to say: Trump’s and the broader Republican war on expertise has been ongoing for a while. We missed our chance to choose a different path in 2024 and now may be approaching the later stage in Hemingway’s account of how one falls into bankruptcy: gradually then suddenly.

To be sure, it is still possible to revive a US commitment to scientific inquiry (and hence to all the human flourishing that flows from such work). But even if we try in 2027 or 2029, we’ll be doing so from deeper in the hole and with a much harder row to hoe than was possible when what follows was written.

Still, to steal from what John F. Kennedy said sixty four years ago in a related context, “there is new knowledge to be gained, and new rights to be won, and they must be won and used for the progress of all people…that challenge is one that we are willing to accept, one we are unwilling to postpone, and one we intend to win…”

And with that, here is an essay I wrote seven years ago during Trump I. Read on for an account of some of what got us into this mess, originally published in The Boston Globe on April 4, 2019.

show full post on front page

It Was Nice While It Lasted…The US Surrenders on SciencePost + Comments (40)

IN EARLY 2019, American journalists sounded a warning: China was about to — no, scratch that — has figured out how to monopolize the 21st century economy by seizing control of 5G,the next generation of super high speed internet. Critics fear that because the Chinesedeveloped it first, they will have exclusive access to the technology behind a new, fully interconnected version of the Internet, delivering it through a network of Chinese-only fiber-optic connections designed to work only with Chinese made equipment.

Game over; the Chinese have won.

Writing in Wired, Susan Crawford warned that if the Chinese take control of the 5G ecosystem, “American companies don’t stand a chance,” while David Brooks in The New York Times proclaimed that “It’s become increasingly clear that China is a grave economic, technological andintellectual threat to the United States and the world order.”

These prophecies have a familiar ring. Not long ago, Japan was going to dominate modern manufacturing; and at one point, reasonable people feared that Microsoft’s Windows operatingsystem would concentrate too much computing control into a single private company’s hands.

Then, as now, such fears can cross over into outright racism. Brooks, for example, asks if China is the “other,” a framing device that depicts economic adversaries as inherently

different — and less worthy — than ourselves.

Regardless of such economic and potentially nationalistic concerns, the focus on China’s potential 5G dominance misses a subtler shift at work, with stakes that go far beyond immediate commercial opportunities.

Which nation will drive the study of our universe over the next century? Since World War II, America has been the unquestioned leader in basic scientific research, especially curiosity-driven inquiry that underpins many of the signature technological advances on which we now depend. A shift in scientific power will have far-reaching consequences. If the US loses its dominance over scientific research, the consequences will exceed — and outlast — any short-term commercial gains.

If our scientific dominance ends, it will not be because of Chinese perfidy, but because the US chose to surrender its commanding role in the search for knowledge – and by doing so, abandoned a unique and often overlooked source of American power.

THE AMERICAN SCIENTIFIC century effectively began on July 16th, 1945, when the world’sfirst nuclear weapon detonated in a remote corner of the New Mexico desert. For Vannevar Bush,who had helped oversee the Manhattan Project, the lesson of the Trinity test was obvious: America, now armed with the atomic bomb, should refocus its power and resources on maintaining its lead in an increasingly science-driven race for international wealth and power.

Shortly thereafter, Bush delivered a report to President Truman titled Science: The EndlessFrontier. Part manifesto, part roadmap, Bush’s report promoted a single idea: that 20th century progress — in medicine, industry, and invention — would “require continuous additions to knowledge of the laws of nature.”

He noted that the extraordinary advances made during the war years, including nuclear weaponry, mass production of antibiotics, radar, code-breaking, and computing, had all depended on curiosity-driven scientific inquiry. If you focused on solving specific commercial problems, Bush argued, you would miss the fundamental ideas that produce much larger and bolder advances. “This essential, new knowledge,” he told Truman, “can be obtained only through basic scientific research,” to be funded by the federal government.

It’s difficult now to imagine how radical this was. Before World War II, US basic science had been a relatively small affair, with its biggest projects — the giant telescopes at Mt. Wilson and Mt. Palomar in southern California, or E. O. Lawrence’s atom smashers in Berkeley — generally funded by private philanthropy. The war expanded the reach and cost of science beyond anything private money, even corporate funds, could reasonably support.

Even with the successful use of the atomic bomb to remind Congress how fundamental physics could end a war, it still took five years to build a coalition willing to inject the federal funds into basic science inquiry. In 1950, the National Science Foundation (NSF) was finally founded,channeling significant money into curiosity-driven research projects and keeping politicians (mostly) out of the loop. Funding decisions were made by scientists and domain experts, not civil servants.

Bush’s vision created a world-leading approach to basic science. Though Nobel prizes are an imperfect measure, with 269 science wins through 2018, US-based researchers have utterly outpaced the second-place nation, Britain, with its 89 Nobels.

More importantly, money spent on basic research produces more discoveries, enhancing anation’s soft power. US astronauts on the moon may not have affected the price of eggs, but did establish America as the most technologically culture on the planet for the next few decades.

Unexpected technological advances have also flowed from seemingly impractical pursuits. For one classic example, the polymerase chain reaction, a Nobel-winning discovery in the 80s that enables the creation of an unlimited number of copies of a stretch of DNA, is one of the basic, essential tools of the modern bioengineering industry. The key to the process was found in the 1960s, by two microbe researchers taking samples in Yellowstone’s hot springs, just to find out how bacteria could survive in the heat. Transistors, invented in the late 1940s, turn on quantum theory. GPS relies on Einstein’s general theory of relativity to make the corrections needed to locate your phone to the stretch of sidewalk you’re passing. Some studies suggest that the economic return on science spending may range up to $80 for each dollar invested.

The frequency of American Nobel wins peaked in 1972. Since then, Claudius Gros writes, awardshave declined “at a continuously accelerating rate.” Why? Certainly not for lack of money. Dr. Marc Kastner, formerly MIT’s dean of science, and now president of the Science Philanthropy Alliance, notes that “US research and development funding has been roughly keeping up our GDP” for the last several years.

But rivals have been accelerating their own funding, especially in China, where, Kastner says, “spending as a fraction of GDP has not reached ours, but is rising rapidly and will surpass ours within a decade.”

China began heavily investing in basic scientific research a mere 25 years ago, but it has quickly dominated the field. The country’s investment in science rose from $9 billion in 1991 to over $400 billion by the mid 2010s. “There has been a huge influx of money into the top 40 to 50universities,” says John Zhang, professor of chemistry at NYU Shanghai. “That’s had a huge impact in terms of basic research.”

China is now approaching US levels of research investment: In a 2018 National Science Foundation report, the US still leads with $497 billion in research and development spending as of 2015, or about 26% of the world’s total investment. But China is a close second, at $409 billion.

And by one measure, any appreciable gap has disappeared. In 2016, China-based scientistsbecame the world’s most prolific scientific authors, exceeding US researchers in numbers of paper published 426,000 to 409,000. That said, American and European papers continue to be more frequently cited by researchers than Chinese papers.

Some observers argue that institutional obstacles in China will continue to hinder researchers in that country from doing their best work. Zhang says that up until very recently, funding agencieshave graded researchers on a strict quantitative formula: how much they’ve published, and the prestige of the journals in which that work appeared.

That rigid framework tended “to encourage researchers to follow the hot trend in the United States,” he says. As a result, he concludes, “there is a lack of innovation.” Zhong-Lin Lu, a neuroscientist at the Ohio State University, who is also affiliated with NYU Shanghai, agrees. He says that “the goal has been to publish in high impact journals, not to build solid researchprograms. [China] is pumping a lot of money into the system, but I don’t see a lot of really good outcomes.”

But Zhang also notes that these kinds of funding directives may be changing, allowing Chinese researchers more latitude. Further, the Chinese have advantages in fields of research which “require a lot of labor,” like gene sequencing or large-scale animal studies. “10,000 rats would be hard to do in the US,” Lu says. “That’s easy in China.”

LAST YEAR AT MIT, the prospect of an imminent Chinese scientific dominance seemed to come true. On 12 April 2018, Jianwei Pan, Vice President of the University of Science and Technology in China, led a session of MIT’s prestigious Physics Department colloquium where he describedhis group’s series of experiments probing a phenomenon called quantum entanglement — a fundamental property of the micro-universe, vital to the emerging technology of quantum computing. For two hours, Pan described how they were testing their ideas, from tabletop setups to a satellite that sends quantum signals across the globe.

Physicist and historian of science David Kaiser works on some of the same problems and, he says,“I expected to hear about the results in the cool work I knew about.” Instead, “the biggest result was the extraordinary scale of all the things [Pan] has been able to do. Pan and his colleagues can think up remarkable new ideas and set right to work to pursue them.”

Kaiser says that he felt pangs of envy when Pan described his seemingly limitless access to resources in China, similar to what foreign scientists 50 years ago might have experienced when an American particle physicist came to town. In those days, Kaiser says, “No project was out of range. If you could think it, you could go do it. It hasn’t felt like that in American physics for decades.”

Scientists follow opportunities. In the ’30s, refugees from fascist Europe helped jumpstart American science. Federal funding at the time enabled US universities to attract the best and thebrightest from all over the world. And American doors were open to international talent.

Now, as the US becomes both less reliable as a funder of basic science and, in the age of Trump, more hostile to immigrants, it loses its ability to recruit the best minds. A decade ago, Kastner says, many scientists working in his sub-discipline of materials science would try to stay in theUS. Now, he says, “we’ve started to see students from China going back.” Unchecked, such developments will lead to the erosion of American economic and technological power.

THE RECENT CONCERNS over 5G technology and other shifts in scientific may encompass both legitimate grievances and, sadly, xenophobic arguments that the US can only lose to foreigners if they cheat. It is true that intellectual property has been bitterly contested between China and the US (and other trade partners) in recent years — and that many nations, including China (and theUS), engage in various forms of espionage to gain an edge.

But there’s no treachery involved when China channels Vannevar Bush. It’s hardly cheating to decide to funnel cash into applied research — in artificial intelligence, materials science, and biomedicine, to name a few of China’s priorities — along with basic inquiry. Where’s the sabotage in choosing to spend more as a percentage of GDP on science, in the hope of getting the same results the US won when it did the same 70 years ago? And consider this: Scientific investment isn’t even that expensive. The $8.6 billion for a border wall sought inPresident Trump’s latest budget request, for example, would more than double the NSF’s research spending per year.

All of which is to say that if China’s expanding intellectual ambition worries Americans, we have a simple solution: Welcome as many people as possible who seek to work into American labs. Andcome up with the cash. Spend more. Boost the share of wealth the US devotes to science, including, vitally, that part of the work that seems, at first, to have little or no connection to everyday experience.

©2019 Boston Globe Media Partners, LLC; reprinted by agreement between the writer and the Globe.

And with that: this thread is as open as either path a mouse could choose in a Y maze experiment.

Image: Claude Monet, Train in the Snow, 1875.

Respite: Antimatter To Go Edition

by Tom Levenson|  March 25, 20264:12 pm| 120 Comments

This post is in: Open Threads, Respite, Science & Technology

I’ve got a ton of rage-inducing stuff in the pipeline which I hope to start putting up here and there soon. But I promised some respite, and I’m a content-generator of my (often deadline-missing) word, so here’s a bit of fun for your Wednesday afternoon.

Humankind has just witnessed its latest never-before achievement. Yesterday a truck hit the road within the CERN campus near Geneva. It was transporting very, VERY carefully a cargo created within that laboratory, Europe’s particle physics research center.

That cargo was antimatter. To be precise, that truck transported a grand total of 92 antiprotons, produced in a facility at CERN known informally as the antimatter factory.

Antimatter is just like the ordinary matter you and I are made of, but for one crucial difference: each of its particles has the opposite charge of its ordinary matter counterpart. An antiproton has a negative charge instead of the positive charge of the protons in the nuclei in every atom in our bodies/the universe, for example. (There are a handful of other reversed properties, but that’s the gist.)

One other thing: matter and its anti- counterpart really, REALLY don’t like each other. If an anti-proton comes into contact with a scrap of ordinary matter, it goes BOOM!—the two particles annihilate.

Respite: Antimatter To Go Edition

So antimatter is hard to make in a world full of the other stuff, and once created (which CERN does by ramming protons into metal targets and then capturing a small fraction of the anti-protons created in the flash of collision energy), is even harder to preserve.

To simplify a lot, the way to hang on to antimatter in this vale of tears is to trap it in such a way that it never comes into contact with its surroundings. Doing so requires extreme cold—four degrees K above absolute zero; as near a complete vacuum as technically achievable; and superconducting magnets to hold the antiprotons in a tight enough grasp to ensure they never strike the sides of the containment vessel.

This is not an easy task in a lab. Now imagine what it would take if an antiproton developed an urge for going.* The need to figure out how to transport antimatter arose because the CERN is an electromagnetically busy place, and some of the experiments researchers hoped to perform with antimatter couldn’t be done except in a much more pristine setting—which is being built in Dusseldorf, Germany, 700 kilometers from Geneva.

So the laboratory’s antimatter folks found themselves in the trucking business. Getting antiprotons to become rolling cargo involved designing a traveling version of the containment technology used in the lab. Today marked the first test of the system. A box truck set off on what accumulated into a half-hour, eight kilometer drive—a careful journey, topping out at forty-two kilometers per hour.

Antimatter is implicated in a range of fundamental questions, among them, why there is so much matter and so little antimatter in our universe (which is a good thing from a wholly selfish point of view; if the Big Bang had generated equal amounts of both forms of matter, as some calculations suggest it could have, then there’d be nothing in our neighborhood but the residue of the vast mutual annihilation of the two species of particles). So there’s a lot riding on the ability first to create a storable stock of antiparticles and then to get it into the right environment for ultra-precise measurement.

A five mile jaunt on a secured right of way is only the beginning. It will be a while yet before you can DoorDash an order of anti-hydrogen with some frites on the side. But it is amazing for all of that. Human beings have managed to reach into the realm previously reserved for action on a cosmological scale—and now the antimatter show has hit the road.

To put this another way: we just witnessed the Winter Olympics. We saw extraordinarily accomplished people do exceptional things. While almost every last person watching will never attempt, much less land, a quad axel or a 1620 rotation on a freestyle jump, it is thrilling to witness, to know it can be done.

Same here, learning of those 92 antiprotons made it out and back safely using machinery that is at the very limit of what humankind knows how to build.

More detail at the source for this post.

*Inevitable soundtrack. Inevitable alternate soundtrack.

Image: Joseph Stevens, Enemies, 1854

Respite: Antimatter To Go EditionPost + Comments (120)

Respite: At Play in the Fields of the LLMs

by Tom Levenson|  March 1, 20266:17 pm| 109 Comments

This post is in: Open Threads, Respite, Technology, General Stupidity

ETA: This was written for Balloon Juice but is crossposted at Inverse Square.

So…

Just this week I learned that through my home institution I have access to a suite of LLMs, including all the usual suspects (Anthropic’s Claude, OpenAI’s ChapGPT, Meta’s Llama, and Google’s Gemini. MIT’s come up with a very nice interface to interact with all this artificial talent, and I’ve spent a couple of hours this weekend taking some of them out for a spin. (I’m avoiding OpenAI’s offerings both as a trivial protest and because I don’t trust anything about that company.

So far I’ve enjoyed Claude the most (the Haiku 4.5 model, if you’re wondering). Gemini is interesting, if a bit finicky. But what made me howl was the encounter I just had with Llama, Mr. Zuckerberg’s contribution to the genre. Context: over the holidays I  had a conversation with a senior person at another magnificent 7 tech firm who’d just seen a colleague leave to go to Meta who was utterly dismissive of the company and relieved to be rid of anyone dumb enough (in his view) to basically end his career in top-tier tech by grabbing Facebook bucks. Spoiler: after what you’ll read below, I can see where my friend was coming from.

So here’s the setup. I’ve been asking the various models what I hope are zero-consequence questions, queries in which no one could possibly get hurt if the LLMs wing their way to utter bollocks. A typical ask: map out the logical structure Einstein used in his 1905 light quantum behavior. That one tended to get an initial poor answer based on the idea that the paper centers on the then-pressing mystery of the photoelectric effect–a common mistake for people as well as machines. Pressing the models led Claude in particular to a much more sophisticated account of the paper drawing attention to the way Einstein used arguments from thermodynamics to propose the necessity of understanding light as discrete packets of energy.

Respite: At Play in t

The paper was about this new “heuristic” [Einstein’s term] view of light, and the photoelectric effect appears only as one experimental support for that view. (Much more here.)

After three or four trips through the query engineering needed to get a useful result I’d found my way down the list of models at my disposal to Meta’s Llama.  I was bored with light quanta and so asked a different, much simpler question:

“When a stock is overvalued as defined by a price to earnings ratio a standard deviation or more higher than historical market norms for that company’s sector, what are the typical events or analyses that drive that share price back down to the norm?”

Llama gave me a very stock answer that would have been at home in a high school economics class, so I decided to become a little more pointed in my pursuit:

Given that analysis, how would you explain Tesla’s long run of share prices between one and two orders of magnitude over that of other and much larger and more profitable car companies, like Toyota?

What followed was…first unimpressive and then hilarious. See for yourselves below the jump:

show full post on front page

Respite: At Play in the Fields of the LLMsPost + Comments (109)

Tesla’s Valuation Puzzle

Tesla’s share price has been a subject of fascination and debate, with its valuation often being significantly higher than that of other automakers, including Toyota. To understand this phenomenon, let’s examine the factors that have contributed to Tesla’s premium valuation.

Growth and Disruption

  1. Pioneering electric vehicles (EVs): Tesla was one of the first companies to successfully mass-produce EVs, creating a new market and disrupting the traditional automotive industry.
  2. Innovative technology: Tesla has been at the forefront of EV technology, with advancements in battery management, autonomous driving, and software updates.
  3. Brand loyalty and cult following: Tesla has built a strong brand identity, with a loyal customer base and a reputation for innovation and sustainability.

Investor Sentiment and Expectations

  1. Growth expectations: Investors have high expectations for Tesla’s future growth, driven by its expanding product lineup, increasing production capacity, and potential for further market disruption.
  2. Long-term vision: Tesla’s mission to accelerate the world’s transition to sustainable energy has resonated with investors, who are willing to look beyond short-term profitability.
  3. Charismatic leadership: Elon Musk’s leadership and vision have been instrumental in shaping Tesla’s brand and driving investor enthusiasm.

Valuation Metrics and Comparisons

  1. Price-to-earnings (P/E) ratio: Tesla’s P/E ratio has often been significantly higher than that of traditional automakers, reflecting its growth prospects and investor expectations.
  2. Price-to-sales (P/S) ratio: Tesla’s P/S ratio has also been elevated, indicating that investors are willing to pay a premium for its revenue growth.
  3. Comparison to other growth stocks: Tesla’s valuation has been compared to that of other growth stocks, such as Amazon or Shopify, which have also experienced significant premium valuations.

Challenges and Risks

  1. Competition from established automakers: Traditional automakers, including Toyota, have been investing heavily in EV technology, potentially eroding Tesla’s competitive advantage.
  2. Production and delivery challenges: Tesla has faced production and delivery issues in the past, which can impact its ability to meet growth expectations.
  3. Regulatory risks: Changes in government policies or regulations can affect Tesla’s business, particularly if they impact the demand for EVs or the company’s access to incentives.

Why Tesla’s Valuation Has Remained High

Despite the challenges and risks, Tesla’s valuation has remained high due to a combination of factors:

  1. Continued growth and innovation: Tesla has continued to innovate and expand its product lineup, maintaining its position as a leader in the EV market.
  2. Investor enthusiasm and momentum: The company’s strong brand and charismatic leadership have maintained investor enthusiasm, driving the stock price higher.
  3. Speculative buying and short squeezes: Tesla’s stock has been subject to speculative buying and short squeezes, which can contribute to its high valuation.

Comparison to Toyota

Toyota, on the other hand, is a more established automaker with a larger market capitalization and a more diversified product lineup. While Toyota has been investing in EV technology, its valuation has been more in line with traditional automakers. The key differences between Tesla and Toyota are:

  1. Growth prospects: Tesla is expected to continue growing at a faster rate than Toyota, driven by its focus on EVs and innovative technology.
  2. Brand identity and disruption: Tesla has created a new market and disrupted the traditional automotive industry, whereas Toyota is a more established player with a different business model.

In conclusion, Tesla’s high valuation relative to Toyota and other traditional automakers can be attributed to a combination of factors, including its growth prospects, innovative technology, brand loyalty, and investor enthusiasm. While there are challenges and risks associated with Tesla’s business, its continued innovation and growth have maintained its premium valuation.

I saw a few problems with that conclusion, so I asked again:

I’d like you to follow up on that analysis. You say Tesla has an expanding product lineup; it has just discontinued its two largest models (Model S and Model X). The cybertruck has failed to become a mass market vehicle. And global sales are declining while Tesla has been overtaken by BYD as the world’s largest EV maker. Its innovation process has slowed, and it is arguably behind Waymo and others in autonomous driving. Its leader is a controversial figure, whose presence energizes one community but since 2024 at least has alienated another, arguably of those more likely to buy an EV. Are you sure that these are the factors that explain Tesla’s share price? Or to put it another way, would you invest Meta’s money in Tesla at the current P/E ratio?

What followed is, it seems to me, a perfect anecdata demonstration of why we might not want to surrender all of our critical faculties to a set of silicon overlords. Map what Llama says onto what I asked:

Revisiting Tesla’s Valuation

Upon further analysis, it appears that the factors I previously mentioned may not be as relevant as they once were. Tesla’s product lineup has indeed been contracting, with the discontinuation of its two largest models, the Model S and Model X. The Cybertruck, while innovative, has not achieved mass market success. Additionally, Tesla’s global sales have been declining, and the company has been overtaken by BYD as the world’s largest EV maker.

Challenges and Concerns

  1. Declining sales and market share: Tesla’s sales have been declining, and the company has lost its position as the world’s largest EV maker.
  2. Innovation slowdown: Tesla’s innovation process has slowed, particularly in the area of autonomous driving, where it is being surpassed by competitors like Waymo.
  3. Controversy surrounding Elon Musk: Elon Musk’s leadership and behavior have become increasingly polarizing, potentially alienating a significant portion of potential customers.

Reevaluating Tesla’s Valuation

In light of these challenges and concerns, it’s reasonable to question whether Tesla’s current valuation is justified. The company’s P/E ratio is still relatively high, indicating that investors are willing to pay a premium for its shares.

Investment Decision

If I were to advise Meta on investing in Tesla at the current P/E ratio, I would likely recommend caution. While Tesla is still a pioneering company in the EV space, its current challenges and concerns suggest that its growth prospects may be more limited than previously thought.

Alternative Investment Opportunities

There may be other investment opportunities in the EV or technology spaces that offer more attractive growth prospects and valuations. For example, companies like BYD, NIO, or Li Auto may offer more compelling investment opportunities due to their growth potential and competitive positioning.

Conclusion

In conclusion, while Tesla is still a significant player in the EV market, its current challenges and concerns suggest that its valuation may be due for a correction. As an investor, it’s essential to carefully evaluate the company’s prospects and consider alternative investment opportunities before making a decision. At the current P/E ratio, I would likely advise against investing in Tesla, and instead, explore other opportunities that offer more attractive growth prospects and valuations.

That’s a 180 degree swing from the prior answer, generated by nothing more than calling bullshit on the model’s first conclusion.

What does it all mean?

Hell if I know. I’m as far from an expert on all of this stuff as it’s possible to be. I’m just a guy with access to a very funny set of hammers out here looking for nails.

One thought though: there’s a lot of evidence out there, some of which I’ve encountered directly from colleagues and friends, in which various AI approaches have real and large impacts on various problems. Folks doing drug discovery or protein analysis or a lot of coding tasks and…well the list goes on. And in just my brief playtime with Claude et al., I got some distinct value from the LLMs’ ability to look at specific texts and break them down. So anyone saying AI is a fraud top to bottom is, I think, clearly wrong.

But those who think that a general machine intelligence is right around the corner…well, the Llama case above seems to me a pretty clear example of how a statistical inference machine operating on a bucket full of internet slop may not be all that, not yet and quite possibly not for an arbitrarily long time to come.

Image: J. M. W. Turner, Keelman hauling coals by moonlight, 1835

Respite: Some Vaccine Good News

by Tom Levenson|  February 20, 202611:08 pm| 20 Comments

This post is in: Healthcare, Open Threads, Respite, Science & Technology

Meant to get this up earlier, but life got in the way,  so I’m just going to post this anyway, just to give us some good news to chew on.

First up on what I guess we can call vaccine Friday: we can now immunize you against a whole bunch of nasty viruses all at once–if you’re a mouse.

Quick Respite/Reminder: Vaccines Are...Kinda Good, Ya Know

This is from the Nature summary of the research, which was published today in Science.

Imagine if a nasal spray could make you immune not only to the viruses that cause COVID-19 and influenza, but to all respiratory diseases. In a paper1published in Science today, researchers describe a vaccine that has done just that. When given to mice, the vaccine protected them for at least three months against multiple disease-causing viruses and bacteria — including the SARS-CoV-2 virus that causes COVID-19 — and even quelling responses to respiratory allergens.

What’s coolest about this (to my historically inclined mind) is that the research that led to this new “universal” vaccine began with an investigation of an old one, the Bacillus Calmette–Guérin (BCG) vaccine. BCG was developed over more than half a century in Germany and France in an effort that began with the isolation of the bacterium that’s the pathogen behind bovine tuberculosis, and culminated with work at the Pasteur Institute that followed Louis Pasteur’s signature move of attenuating a disease-causing microbe until it could induce immunity without making the person receiving the jab sick. It became the first vaccine for tuberculosis in 1921.

Fast forward a century, and the mechanism of action in that vaccine–activating the latent immune system, which, as Liam Drew writes in that Nature summary, is an  “evolutionarily ancient system [that] has a much broader reactivity than does the adaptive immune system”–led researchers to this:

In the latest study, Pulendran’s team developed a universal vaccine that targets the innate immune system, with three components. The first two are drugs that stimulate specific receptor proteins that can activate innate immune cells, such as macrophages that reside in the lungs. [link in the original]

The third component stimulates a population of T cells, which are part of the adaptive immune system. Their task is to keep sending signals to the innate immune system to maintain its active state.”

The vaccine works a treat in mice, but, as the linked Nature news piece makes clear, there are significant hurdles to overcome to create a safe and effective human version. But even so, this is a necessary and genuinely exciting first step.

The second bit of good vaccine news–not so much “good” as “promising” or potentially valuable–comes from a very early human trial of personalized mRNA vaccines for triple-negative breast cancer, a particularly nasty and intractable form of disease in which the cancer cells lack targets for the three most common drugs for the condition.

A paper published in Nature a couple of days ago provided the results of a trial of a vaccine approach that in essence persuades patients’ immune systems to react to the drugs, using mRNA as the vector–or as the clinical brief summary put it:

We conducted an exploratory trial of these personalized vaccines to assess their feasibility, safety and mechanism of action, rather than clinical benefit. We genetically sequenced tumour cells and healthy cells from 14 individuals with early-stage, surgically removed TNBC and used algorithms to select mutations that generate neoantigens. For each participant, we manufactured a personalized mRNA vaccine encoding up to 20 neoantigens. Once administered intravenously, the vaccine reaches lymphoid organs, where T cells are taught how to recognize the mRNA-encoded neoantigens.

This trial was intended to test the feasibility of the approach, but it did have an impact on the patients involved:

Ten participants remained disease-free, and one participant died of unknown causes. Relapse occurred in three individuals, enabling us to gain insights into possible resistance mechanisms.

Again–very early work, miles to go before we sleep, and caution around any small scale cancer study is not just warranted but required. Still, another exciting first step.

In sum: A) science is so cool. And B) while this is a respite post, I’d be remiss if I didn’t add that this is reason ∞ that RFK Jr.’s antivaccine crusade–and his anti-mRNA technology pathology in particular–is such a disaster. Both of the studies above are fine preliminary research results. They won’t mean anything if the next stages of the work don’t happen, and if the US scientific shut down continues for much longer, the basic science that won’t get done will prevent any new such leads to appear. Worse, the damage so far to ongoing research program is such that we’ve already lost potential advances in human flourishing.

So yes, this is all good news. But there’s a lot of work to be done to make it possible for more such promising outcomes to arrive down the road.

Happy weekend, everyone. The thread, as usual, is open.

[Crossposted at Inverse Square]

Image Zhu Zhenji, Mouse and stone, 1427.

Respite: Some Vaccine Good NewsPost + Comments (20)

The Vaccine Crisis…It’s here.

by Tom Levenson|  February 16, 20268:04 pm| 14 Comments

This post is in: Healthcare, Open Threads, Republican Stupidity

NB: Another cross post with Inverse Square. As ever, if you would like to get email notifications of these regrettably uncheery updates (and some happier ones, I hope) you can subscribe over there.

——————————-

Sometimes, working on a book means that you see references to your work everywhere you look, when what’s really going on is that you (me, to be honest) only retains stuff that connects with your (my) obsession of the moment.

Other times, though, it really is all about whatever it is I’m most deeply engaged with at the moment.

As now.

The vaccine crisis is real, much more imminently threatening than I dreamed a year ago, when I started working on a polemical history of objections to vaccination.

Rebecca Robins captures the current state of play in her story today in the New York Times. The headline and its subhed pretty much say it all: “Vaccine Makers Curtail Research and Cut Jobs” followed by “Federal policies under Robert F. Kennedy Jr. that are hostile to vaccines have “sent a chill through the entire industry,” one scientist said.”

The rest of the piece lays out in detail what’s going wrong. There’s a flat rejection of the most promising new vaccine approach, the use of mRNA technology, which that noted virologist and molecular biologist Robert Kennedy tells is not effective. (He’s neither, of course, and he’s flat wrong.) There’s a sustained discouragement of vaccination coming down from the top ranks of US public health, starting with lopping off one third of the list of (formerly) recommended childhood vaccines. (Measles, pertussis, and now mumps all thank Secretary Kennedy.) And Robins writes of perhaps the most potent weapon anti-vax campaigners at HHS have to shadow ban most or all vaccines: revising the current vaccine injury compensation system to expose vaccine makers to unlimited liability for alleged harms. That would mark a return to the way it was in the 1970s and 80s, when almost all vaccine manufacturers were driven from the US market. No need to prohibit immunization if it’s impossible to buy a shot.

Even before that, trials of potentially major new vaccines are on hold, at best. Say goodbye for the time being to possible preventatives for strep infections, for shigella, for the flu (one of the mRNA vaccines sacrificed on the altar of Kennedy’s utterly convinced ignorance), for Epstein Barr syndrome, with, I’m sure, more retreats to follow.

The Vaccine Crisis...It's here.

As Robins writes, each of those at least temporarily abandoned shots fell to business decisions, which presumably could be reversed if/when political winds shift. Another story, this one from the Boston Globe points to a less reversible loss: A brain drain (the paper’s term) of biomedical investigators that already is eroding the US research enterprise across the spectrum of medical research, very much including vaccine science.

The key takeaway from this piece, which is based on a survey of Massachusetts scientists, is that once you halt work in a lab–no matter how close that lab might be to a breakthrough–not only is that immediate result gone, the capacity to return to that research collapses too. Teams scatter, informal knowledge evaporates, and any prior results, the accumulation of insights that lead to something important, don’t travel intact as the various groups scatter.

Which is to say that the damage Trump, Kennedy, et al. doesn’t end when they lose power. It will take years—decades, quite possibly—to rebuild the scientific infrasture that we had just a little over twelve months ago. Other nations will pick up some of our people and with them the intellectual possibilities our research surrender has created.

But potential advances will be slowed, perhaps some actually lost for the foreseeable future. And for vaccines themselves, all those infections, the illnesses and deaths that could have been prevented by existing vaccines or the new ones that are now indefinitely delayed—that burden of misery will accumulate day by day until we finally get back to the status quo ante.

None of this needed to happen, but here we are. One job we need to do (and this post is part of that effort) is to make sure that Kennedy and his allies own every harm, every loss they’re inflicting on the American people. Another is to do whatever we can at the state level and with private money to save as much of American science as we can.

I wish I had something happier to write about. When I get good news, I promise to shout it from the rooftops. In the meantime I’ll just say that Paul Krugman speaks for me at the end of his post today on the madness of Trump’s energy “policy:”

For the most part, all MAGA will do is help make the United States backward, poorer, sicker and irrelevant.

Yes, yes, and yes.

This thread is as open as RFK Jr.’s mind is closed.

Image: Illarion Mikhailovich Pryanishnikov, French Retreat in 1812, 1874.

The Vaccine Crisis…It’s here.Post + Comments (14)

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 201
  • Go to Next Page »

Primary Sidebar

On The Road - SkyBluePink - Skies of blues & pinks 2
Photo by SkyBluePink (4/14/26)
Donate

Election Resources

Voter Registration Info – Find a State
Check Voter Registration by Address
Election Calendar by State

Targeted Fundraising Info & Links

Recent Comments

  • Elizabelle on War for Ukraine Day 1510: Putin Lashes Out (Apr 15, 2026 @ 4:04am)
  • Elizabelle on War for Ukraine Day 1510: Putin Lashes Out (Apr 15, 2026 @ 3:55am)
  • Jay on War for Ukraine Day 1510: Putin Lashes Out (Apr 15, 2026 @ 3:42am)
  • Jay on War for Ukraine Day 1510: Putin Lashes Out (Apr 15, 2026 @ 3:40am)
  • Elizabelle on War for Ukraine Day 1510: Putin Lashes Out (Apr 15, 2026 @ 3:37am)

Balloon Juice Posts

View by Topic
View by Author
View by Month & Year
View by Past Author

Featuring

Medium Cool
Artists in Our Midst
Authors in Our Midst

🎈Keep Balloon Juice Ad Free

Become a Balloon Juice Patreon
Donate with Venmo, Zelle or PayPal

Calling All Jackals

Site Feedback
Nominate a Rotating Tag
Submit Photos to On the Road
Balloon Juice Anniversary (All Links)
Balloon Juice Anniversary (All Posts)

Fix Nyms with Apostrophes

Outsmarting Apple iOS 26

Balloon Juice Mailing List Signup

Order Calendar A
Order Calendar B

Social Media

Balloon Juice
WaterGirl
TaMara
John Cole
DougJ (aka NYT Pitchbot)
Betty Cracker
Tom Levenson
David Anderson
Major Major Major Major
DougJ NYT Pitchbot
mistermix
Rose Judson (podcast)
Sister Golden Bear

Donate

Site Footer

Come for the politics, stay for the snark.

  • Facebook
  • RSS
  • Twitter
  • YouTube
  • Comment Policy
  • Our Authors
  • Blogroll
  • Our Artists
  • Privacy Policy

Privacy Manager

Copyright © 2026 Dev Balloon Juice · All Rights Reserved · Powered by BizBudding Inc